The News
Catch the latest updates as CTMC drives innovation in cell therapy to accelerate development and manufacturing
to impact patients sooner
Press Releases
Novel CAR T cell therapy developed by UT MD Anderson researchers moves into clinical studies
The novel therapy targets CD94+ relapsed or refractory T/NK cell lymphomas UT MD Anderson received Investigational New Drug clearance from the Food...
CTMC and Einstein Hospital Israelita in Brazil Partner to Launch the Global Cell Therapy Network Alliance
The CTMC Network Alliance aims to democratize and accelerate cell therapies to cancer patients globally Read the full press release: CTMC - Einstein...
CTMC Appoints Amy Hay as Chief Business Officer and Duane Avant as Chief Technical Officer
HOUSTON, TX, February 5, 2025 — CTMC, a joint venture between Resilience and MD Anderson Cancer Center, has appointed Amy Hay as Chief Business...
Recent News
How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?
Read the full article here: Pharma's Almanac
Cell Therapy Manufacturing: A Medicine Maker’s “Dream”
Why CTMC CEO Jason Bock relishes the challenge of solving cell therapy’s most complex manufacturing and delivery problems Read the full article...
Part 2: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez
When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from...
Part 1: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez
The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the...
Base to Base biotech podcast #55: The circular supply chain
CTMC is a joint venture between Resilience and the MD Anderson Cancer Center. It works like an internal manufacturing group, adapting to change...
Pairing up to advance CAR T cell therapies: a dual-targeting approach to solid tumours
A partnership between Link Cell Therapies and CTMC is advancing next-generation CAR T therapies for solid tumours by combining dual-targeting...
2026 Cell and Gene Therapy Predictions
For CGTs, this will be the year where the rubber meets the road, according to industry thought leaders Read all the predictions here:...
Tying Advanced Biomanufacturing to a Clinic
read the article here: https://www.genengnews.com/topics/bioprocessing/tying-advanced-biomanufacturing-to-a-clinic/
Democratizing Cell Therapy Through Regional Manufacturing | Amy Hay (Part 4/4)
Host Jon Chee sits down with Amy Hay to hear about how CTMC bridges academia and industry to help lean cell therapy teams reach the clinic faster...